These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17531080)

  • 1. Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro.
    Fierro F; Illmer T; Jing D; Schleyer E; Ehninger G; Boxberger S; Bornhäuser M
    Cell Prolif; 2007 Jun; 40(3):355-66. PubMed ID: 17531080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt- and Erk-mediated regulation of proliferation and differentiation during PDGFRβ-induced MSC self-renewal.
    Gharibi B; Ghuman MS; Hughes FJ
    J Cell Mol Med; 2012 Nov; 16(11):2789-801. PubMed ID: 22805337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
    Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow.
    Soares PB; Jeremias TS; Alvarez-Silva M; Licinio MA; Santos-Silva MC; Vituri CL
    Braz J Med Biol Res; 2013 Jan; 46(1):39-51. PubMed ID: 23011404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
    Ruan J; Luo M; Wang C; Fan L; Yang SN; Cardenas M; Geng H; Leonard JP; Melnick A; Cerchietti L; Hajjar KA
    Blood; 2013 Jun; 121(26):5192-202. PubMed ID: 23632889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalytically inactive SHIP2 inhibits proliferation by attenuating PDGF signaling in 3T3-L1 preadipocytes.
    Artemenko Y; Gagnon A; Sorisky A
    J Cell Physiol; 2009 Jan; 218(1):228-36. PubMed ID: 18814181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
    McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
    J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells.
    Dong Y; Han Q; Zou Y; Deng Z; Lu X; Wang X; Zhang W; Jin H; Su J; Jiang T; Ren H
    Mol Cell Biochem; 2012 Nov; 370(1-2):89-102. PubMed ID: 22829019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion.
    Fitter S; Vandyke K; Gronthos S; Zannettino AC
    J Mol Endocrinol; 2012 Jun; 48(3):229-40. PubMed ID: 22474082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro.
    Chung HW; Wen J; Lim JB; Bang S; Park SW; Song SY
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):862-9. PubMed ID: 19801102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
    Malavaki CJ; Roussidis AE; Gialeli C; Kletsas D; Tsegenidis T; Theocharis AD; Tzanakakis GN; Karamanos NK
    FEBS J; 2013 May; 280(10):2477-89. PubMed ID: 23374223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib.
    Mor-Tzuntz R; Uziel O; Shpilberg O; Lahav J; Raanani P; Bakhanashvili M; Rabizadeh E; Zimra Y; Lahav M; Granot G
    Exp Hematol; 2010 Jan; 38(1):27-37. PubMed ID: 19837126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats.
    Schellings MW; Baumann M; van Leeuwen RE; Duisters RF; Janssen SH; Schroen B; Peutz-Kootstra CJ; Heymans S; Pinto YM
    Hypertension; 2006 Mar; 47(3):467-74. PubMed ID: 16432052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
    Aslam MI; Abraham J; Mansoor A; Druker BJ; Tyner JW; Keller C
    Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6383-8. PubMed ID: 24733895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of imatinib mesylate in osteoblastogenesis.
    Tibullo D; Giallongo C; La Cava P; Berretta S; Stagno F; Chiarenza A; Conticello C; Palumbo GA; Di Raimondo F
    Exp Hematol; 2009 Apr; 37(4):461-8. PubMed ID: 19302920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.